

Disclosure of the total number of voting rights and shares as of August 31, 2022

Paris, France, September 9, 2022 - ACTICOR BIOTECH (ISIN : FR00140050J5 – ALACT), a clinical stage biopharmaceutical company dedicated to the development of innovative treatments for cardiovascular emergencies, today discloses the total number of voting rights and shares as of August 31, 2022 (pursuant to Article L. 233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the French Financial Markets Authority).

- Listing Place : Euronext Growth Paris
- ISIN Code : FR00140050J5
- Web site: acticor-biotech.com

Date	Number of shares making up the share capital	Theoretical number of voting rights ⁽¹⁾	Number of voting rights excluding shares stripped of voting rights ⁽²⁾
August 31, 2022	10.545.776	10.545.776	10.492.195

(1) *In accordance with Article 223-111 of the AMF's General Regulation, this number of shares is calculated based on all shares carrying the right to vote, including those stripped of voting rights.*

(2) *The actual voting rights correspond to the total number of voting rights that can be exercised in a general meeting. They are calculated on the basis of the total number of voting rights attached to the total number of shares minus the shares without voting rights.*

About ACTICOR BIOTECH

Acticor Biotech is a clinical stage biopharmaceutical company, a spin-off from INSERM (the French National Institute of Health and Medical Research), that is developing an innovative treatment for acute thrombotic diseases, including ischemic strokes.

Acticor Biotech is developing glenzocimab (ACT017), a humanized monoclonal antibody fragment (Fab) directed against a novel target of major interest, platelet glycoprotein VI (GPVI). Glenzocimab inhibits platelet binding to the thrombus without affecting physiological hemostasis, thereby limiting the risk of bleeding, particularly intracerebral hemorrhage.

In May 2022, Acticor Biotech presented positive results from its Phase 1b/2a study, ACTIMIS, at the European Stroke Organisation Conference (ESOC 2022), confirming the safety profile and showing a reduction in mortality and intracerebral hemorrhage in the glenzocimab-treated group in patients with stroke. The efficacy of glenzocimab is now being evaluated in an international Phase 2/3 study, ACTISAVE, which will include 1,000 patients.

In July 2022, Acticor Biotech obtains "PRIME" status from the European Medicines Agency (EMA) for glenzocimab in the treatment of stroke. This designation will allow the Company to strengthen interactions and obtain early dialogues with regulatory authorities.

Acticor Biotech is supported by a panel of European and International Investors (Karista, Go Capital, Newton Biocapital, CMS Medical Venture Investment (HK) Limited, A&B (HK) Limited, Anaxago, Mediolanum farmaceutici and the Armesa foundation). Acticor Biotech is listed on Euronext Growth Paris, since November 2021 (ISIN: FR00140050J5 – ALACT).

For further information, please go to www.acticor-biotech.com

Contacts

ACTICOR BIOTECH

Gilles AVENARD, MD

CEO and Founder

gilles.avenard@acticor-biotech.com

T. : +33 (0)6 76 23 38 13

Sophie BINAY, PhD

General Manager and CSO

Sophie.binay@acticor-biotech.com

T. : +33 (0)6 76 23 38 13

NewCap

Mathilde BOHIN / Quentin MASSÉ

Investor Relations

acticor@newcap.eu

T. : +33 (0)1 44 71 94 95